The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

Vertex Pharmaceuticals is gearing up to drop its earnings on May 5, and the market’s popcorn is already popped. The company’s ...

The stock's fall snapped a seven-day winning streak.

The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

"It is not some Disney story of just triumph and resilience, it was really hard," Smith tells PEOPLE about his recovery ...

Vertex Pharmaceuticals outpaced the broader market, closing up 1.19% while major indices mostly tiptoed forward. Over the ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $509.47, moving +1.19% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.15% ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.19% to $509.50 Wednesday, on what proved to be an all-around positive ...

FOX Sports' Joel Klatt joins Colin Cowherd to dive into what led to Shedeur Sanders dropping to the fifth round and how he ...

CRISPR Therapeutics' revenue streams currently rely heavily on grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX). The collaboration has yielded Casgevy, a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.